We are live on ! Find out more

Regencell Bioscience

RGC

Market cap $2.61B

5.27 USD

-0.15

2.77%

At close Updated Nov 5, 4:00 PM EST

Pre-market

After hours

5.20

-0.07

1.33%

1 day

-2.77%

5 days

-23.51%

1 month

-27.21%

3 months

-10.22%

6 months

-80.67%

Year to date

-74.34%

1 year

-59.77%

5 years

887.08%

10 years

1,807.35%

About: Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.

Employees: 10

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 100%

Neutral 0%

Negative 0%

RGC Resources: More Likely To Appeal More To Income-Focused Investors

RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.

RGC Resources: More Likely To Appeal More To Income-Focused Investors

United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.

United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) and certain officers.  The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 23, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell is a purported early-stage bioscience company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating th.

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regencell Bioscience Holdings Limited, (“Regencell” or the "Company") (NASDAQ: RGC) investors of a class action on behalf of investors that bought securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell investors have until June 23, 2026 to file a lead plaintiff motion.

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

NEW YORK, June 23, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC). Shareholders who purchased shares of RGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

NEW YORK, June 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline. So what: If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their Options

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 23, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC),.

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

See News Rankings

Price charts implemented using Lightweight Charts™